Accelerate Diagnostics Stock Price, News & Analysis (NASDAQ:AXDX)

$21.39
+0.11 (+0.52 %)
(As of 09/20/2019 04:00 PM ET)
Today's Range
$21.06
Now: $21.39
$21.62
50-Day Range
$16.41
MA: $18.58
$21.79
52-Week Range
$10.23
Now: $21.39
$24.00
Volume160,873 shs
Average Volume207,657 shs
Market Capitalization$1.17 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.72
Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast. Read More…

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AXDX
CUSIPN/A
Phone520-365-3100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.67 million
Book Value$1.06 per share

Profitability

Net Income$-88,330,000.00
Net Margins-1,293.91%

Miscellaneous

Employees287
Market Cap$1.17 billion
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable

Receive AXDX News and Ratings via Email

Sign-up to receive the latest news and ratings for AXDX and its competitors with MarketBeat's FREE daily newsletter.


Accelerate Diagnostics (NASDAQ:AXDX) Frequently Asked Questions

What is Accelerate Diagnostics' stock symbol?

Accelerate Diagnostics trades on the NASDAQ under the ticker symbol "AXDX."

How were Accelerate Diagnostics' earnings last quarter?

Accelerate Diagnostics Inc (NASDAQ:AXDX) announced its quarterly earnings data on Thursday, August, 8th. The medical research company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.02. The medical research company earned $1.81 million during the quarter, compared to the consensus estimate of $2.71 million. Accelerate Diagnostics had a negative return on equity of 170.47% and a negative net margin of 1,293.91%. View Accelerate Diagnostics' Earnings History.

When is Accelerate Diagnostics' next earnings date?

Accelerate Diagnostics is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for Accelerate Diagnostics.

What price target have analysts set for AXDX?

3 equities research analysts have issued 1 year target prices for Accelerate Diagnostics' shares. Their forecasts range from $16.00 to $19.00. On average, they expect Accelerate Diagnostics' stock price to reach $17.50 in the next twelve months. This suggests that the stock has a possible downside of 18.2%. View Analyst Price Targets for Accelerate Diagnostics.

What is the consensus analysts' recommendation for Accelerate Diagnostics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accelerate Diagnostics in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Accelerate Diagnostics.

What are Wall Street analysts saying about Accelerate Diagnostics stock?

Here are some recent quotes from research analysts about Accelerate Diagnostics stock:
  • 1. According to Zacks Investment Research, "Accelerate Diagnostics, Inc. is focused on developing and commercializing instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. The company is developing BACcel(TM) system, a rapid diagnostic platform for diagnosis in life-threatening bacterial infections and OptiChem(R) surface coatings for use in micro arraying components. Accelerate Diagnostics Inc., formerly known as Accelr8 Technology Corp., is based in Denver, Colorado. " (7/10/2019)
  • 2. BTIG Research analysts commented, "Neutral AXDX reported Q1 revenue of $1.75M, short of consensus’ $1.9M forecast. Revenue was down sequentially by 4%. Although we had expected a revenue stepdown given the typical cadence of placements-to- conversions, the magnitude of the decline was less than we expected. In Q1, the company added 75 commercially contracted placements vs. 133 in 4Q18; to clarify, commercial placements refer to customers that have agreed to install and run tests (may or may not be active users). The company still sees a 4-9 month lag before instruments become active. On expectations for 2019, mgmt continues to target 300-400 placements as a full transition to the rental model and more comprehensive body of positive studies may drive up volumes." (5/12/2019)

Has Accelerate Diagnostics been receiving favorable news coverage?

News articles about AXDX stock have trended somewhat negative this week, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Accelerate Diagnostics earned a media sentiment score of -1.3 on InfoTrie's scale. They also gave news headlines about the medical research company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Accelerate Diagnostics.

Who are some of Accelerate Diagnostics' key competitors?

What other stocks do shareholders of Accelerate Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Accelerate Diagnostics investors own include Himax Technologies (HIMX), Magnachip Semiconductor (MX), Fluidigm (FLDM), Universal Display (OLED), BIOLASE (BIOL), ABIOMED (ABMD), Vuzix (VUZI), Alibaba Group (BABA), Gilead Sciences (GILD) and AT&T (T).

Who are Accelerate Diagnostics' key executives?

Accelerate Diagnostics' management team includes the folowing people:
  • Mr. Lawrence Mehren, Pres, CEO, Director and Interim Head of Europe, Middle East & Africa (Age 53)
  • Mr. Steve Reichling, Chief Financial Officer (Age 41)
  • Mr. Ron Price, Sr. VP & Head of Commercial Operations - Americas (Age 55)
  • Mr. Kurt Reinhardt, Head of Operations
  • Dr. Romney M. Humphries, Chief Scientific Officer (Age 38)

Who are Accelerate Diagnostics' major shareholders?

Accelerate Diagnostics' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (3.68%), AXA (3.23%), Vanguard Group Inc. (2.55%), Griffin Asset Management Inc. (1.01%), Chicago Capital LLC (1.00%) and C WorldWide Group Holding A S (0.96%). Company insiders that own Accelerate Diagnostics stock include Jack W Schuler, John Patience, Steven Reichling and Thomas D Brown. View Institutional Ownership Trends for Accelerate Diagnostics.

Which major investors are selling Accelerate Diagnostics stock?

AXDX stock was sold by a variety of institutional investors in the last quarter, including Amundi Pioneer Asset Management Inc., Cadian Capital Management LP, First Republic Investment Management Inc., Artal Group S.A., Trellus Management Company LLC, Natixis Advisors L.P., Morgan Stanley and Wells Fargo & Company MN. View Insider Buying and Selling for Accelerate Diagnostics.

Which major investors are buying Accelerate Diagnostics stock?

AXDX stock was acquired by a variety of institutional investors in the last quarter, including AXA, C WorldWide Group Holding A S, BlackRock Inc., First Trust Advisors LP, River & Mercantile Asset Management LLP, River & Mercantile Asset Management LLP, Griffin Asset Management Inc. and Chicago Capital LLC. Company insiders that have bought Accelerate Diagnostics stock in the last two years include Jack W Schuler, John Patience, Steven Reichling and Thomas D Brown. View Insider Buying and Selling for Accelerate Diagnostics.

How do I buy shares of Accelerate Diagnostics?

Shares of AXDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Accelerate Diagnostics' stock price today?

One share of AXDX stock can currently be purchased for approximately $21.39.

How big of a company is Accelerate Diagnostics?

Accelerate Diagnostics has a market capitalization of $1.17 billion and generates $5.67 million in revenue each year. The medical research company earns $-88,330,000.00 in net income (profit) each year or ($1.62) on an earnings per share basis. Accelerate Diagnostics employs 287 workers across the globe.View Additional Information About Accelerate Diagnostics.

What is Accelerate Diagnostics' official website?

The official website for Accelerate Diagnostics is http://acceleratediagnostics.com/.

How can I contact Accelerate Diagnostics?

Accelerate Diagnostics' mailing address is 3950 South Country Club Suite 470, Tucson AZ, 85714. The medical research company can be reached via phone at 520-365-3100 or via email at [email protected]


MarketBeat Community Rating for Accelerate Diagnostics (NASDAQ AXDX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  257 (Vote Outperform)
Underperform Votes:  257 (Vote Underperform)
Total Votes:  514
MarketBeat's community ratings are surveys of what our community members think about Accelerate Diagnostics and other stocks. Vote "Outperform" if you believe AXDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel